SCHEMBL5137537

SCHEMBL5137537

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1c(Cl)cccc1[N+](=O)[O-])CC1CCCCC1

nearest known ligand 0.34

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.34
NR1D1 P20393 1/20 0.34
HDAC1 Q13547 1/20 0.32
ALDH1A1 P00352 4/20 0.32
HPGD P15428 3/20 0.32
TSHR P16473 2/20 0.32
KDM4E B2RXH2 2/20 0.32
HSD17B10 Q99714 2/20 0.32
CYP3A4 P08684 1/20 0.32
P2RX7 Q99572 1/20 0.31
LMNA P02545 2/20 0.31
TDP1 Q9NUW8 1/20 0.31
CRHR1 P34998 1/20 0.30
BCHE P06276 3/20 0.30
ABCC1 P33527 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135032 0.91 C5AR1 (0.39) C5AR1HDAC1ALDH1A1HPGDTSHR
SCHEMBL5135460 0.87 C5AR1 (0.36) C5AR1HDAC1ALDH1A1HPGDTSHR
SCHEMBL5134976 0.87 C5AR1 (0.37) C5AR1HDAC1ALDH1A1HPGDTSHR
SCHEMBL5135007 0.84 ALDH1A1 (0.35) C5AR1ALDH1A1HPGDKDM4E
SCHEMBL5135152 0.84 C5AR1 (0.41) C5AR1HDAC1ALDH1A1HPGDTSHR
SCHEMBL5135866 0.83 C5AR1 (0.39) C5AR1HDAC1ALDH1A1HPGDTSHR
SCHEMBL5072326 0.83 C5AR1 (0.41) C5AR1NR1D1HDAC1ALDH1A1HPGD
SCHEMBL5138010 0.83 C5AR1 (0.41) C5AR1NR1D1HDAC1ALDH1A1KDM4E
SCHEMBL651501 0.83 C5AR1 (0.44) C5AR1HDAC1ALDH1A1HPGDTSHR
SCHEMBL5135466 0.82 C5AR1 (0.39) C5AR1HDAC1ALDH1A1HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed